Humacyte Statistics

Total Valuation

Humacyte has a market cap or net worth of $281.90 million. The enterprise value is $322.29 million.

Market Cap	281.90M
Enterprise Value	322.29M

Important Dates

The last earnings date was Monday, August 11, 2025, before market open.

Earnings Date	Aug 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Humacyte has 158.37 million shares outstanding. The number of shares has increased by 22.81% in one year.

Current Share Class	158.37M
Shares Outstanding	158.37M
Shares Change (YoY)	+22.81%
Shares Change (QoQ)	+17.85%
Owned by Insiders (%)	7.25%
Owned by Institutions (%)	40.39%
Float	125.19M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	292.73
Forward PS	22.83
PB Ratio	69.26
P/TBV Ratio	68.20
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	394.00
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.45, with a Debt / Equity ratio of 20.72.

Current Ratio	2.45
Quick Ratio	1.82
Debt / Equity	20.72
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-10.60

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-50.18%
Return on Invested Capital (ROIC)	-100.22%
Return on Capital Employed (ROCE)	-94.50%
Revenue Per Employee	$3,718
Profits Per Employee	-$266,945
Employee Count	220
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -73.09% in the last 52 weeks. The beta is 1.90, so Humacyte's price volatility has been higher than the market average.

Beta (5Y)	1.90
52-Week Price Change	-73.09%
50-Day Moving Average	2.36
200-Day Moving Average	3.20
Relative Strength Index (RSI)	35.57
Average Volume (20 Days)	5,792,138

Short Selling Information

The latest short interest is 31.87 million, so 20.12% of the outstanding shares have been sold short.

Short Interest	31.87M
Short Previous Month	32.72M
Short % of Shares Out	20.12%
Short % of Float	25.46%
Short Ratio (days to cover)	7.87

Income Statement

In the last 12 months, Humacyte had revenue of $818,000 and -$58.73 million in losses. Loss per share was -$0.44.

Revenue	818,000
Gross Profit	-80.55M
Operating Income	-111.23M
Pretax Income	-105.70M
Net Income	-58.73M
EBITDA	-103.92M
EBIT	-111.23M
Loss Per Share	-$0.44

Full Income Statement

Balance Sheet

The company has $38.03 million in cash and $83.96 million in debt, giving a net cash position of -$45.93 million or -$0.29 per share.

Cash & Cash Equivalents	38.03M
Total Debt	83.96M
Net Cash	-45.93M
Net Cash Per Share	-$0.29
Equity (Book Value)	4.05M
Book Value Per Share	0.03
Working Capital	30.65M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$104.50 million and capital expenditures -$1.79 million, giving a free cash flow of -$106.29 million.

Operating Cash Flow	-104.50M
Capital Expenditures	-1.79M
Free Cash Flow	-106.29M
FCF Per Share	-$0.67

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-13,598.04%
Pretax Margin	-7,171.27%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Humacyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.81%
Shareholder Yield	-22.81%
Earnings Yield	-21.25%
FCF Yield	-38.46%

Analyst Forecast

The average price target for Humacyte is $11.93, which is 570.23% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$11.93
Price Target Difference	570.23%
Analyst Consensus	Strong Buy
Analyst Count	7
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Humacyte has an Altman Z-Score of -6.82. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.82
Piotroski F-Score	n/a